Volume 27, Issue 4, Pages (December 2016)

Slides:

Advertisements

Similar presentations

Volume 71, Issue 5, Pages (May 2017)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

Volume 187, Issue 6, Pages (June 2012)

Volume 155, Issue 3, Pages (March 1996)

Percutaneous cystostomy drainage for early removing urethral catheter in robotic- assisted laparoscopic radical prostatectomy: Improving on patients' discomfort

Oncological outcomes of high risk prostate cancer patients between robot-assisted laparoscopic radical prostatectomy and laparoscopic radical prostatectomy.

Volume 195, Issue 5, Pages (May 2016)

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand Bannakij Lojanapiwat, Choosak Pripatnanont,

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 68, Issue 4, Pages (October 2015)

Volume 199, Issue 1, Pages (January 2018)

Volume 74, Issue 2, Pages (August 2018)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 51, Issue 4, Pages (April 2007)

Volume 52, Issue 3, Pages (September 2007)

Volume 52, Issue 4, Pages (October 2007)

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 2, Pages (February 2013)

Volume 65, Issue 5, Pages (May 2014)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 74, Issue 1, Pages (July 2018)

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Volume 71, Issue 1, Pages 1-3 (January 2017)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 70, Issue 4, Pages (October 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 70, Issue 5, Pages (November 2016)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 66, Issue 3, Pages (September 2014)

Volume 62, Issue 1, Pages (July 2012)

Volume 70, Issue 5, Pages (November 2016)

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Luis Martínez-Piñeiro European Urology Supplements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Volume 66, Issue 6, Pages (December 2014)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Volume 70, Issue 1, Pages (July 2016)

Survival analysis Diagnostic Histopathology

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Volume 71, Issue 4, Pages (April 2017)

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Axel Heidenreich European Urology Supplements

Highlighting Unmet Needs: Real Patients, Difficult Choices

Management of Prostate Cancer: Global Strategies

Manfred Wirth, Peter Iversen, David McLeod, William See

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Axel Heidenreich European Urology Supplements

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Presentation transcript:

Volume 27, Issue 4, Pages 218-222 (December 2016) The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients Tony Wu, Hsi Chin Wu, Yen Chuan Ou, See-Tong Pang, Yeong-Shiau Pu, Yen-Hwa Chang Urological Science Volume 27, Issue 4, Pages 218-222 (December 2016) DOI: 10.1016/j.urols.2015.11.003 Copyright © 2015 Terms and Conditions

Figure 1 Kaplan–Meier curve of time-to-prostate specific antigen progression: (A) all treated patients; (B) Gleason score (Gle) ≥ 8 versus Gle ≤ 8; and (C) viscera involvement versus bone and lymph nodes only. LNs = lymph nodes; PSA = prostate specific antigen. Urological Science 2016 27, 218-222DOI: (10.1016/j.urols.2015.11.003) Copyright © 2015 Terms and Conditions

Figure 2 Kaplan–Meier curve of overall survival: (A) prostate specific antigen responders versus nonresponders; (B) Gleason score ≥ 8 versus < 8; and (C) viscera involvement versus bone and lymph nodes only. * Median ± standard error (mo). LNs = lymph nodes; PSA = prostate specific antigen. Urological Science 2016 27, 218-222DOI: (10.1016/j.urols.2015.11.003) Copyright © 2015 Terms and Conditions